Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Ridgeback Capital Investments L.P. (CIK 1423994) reported $80.9M across 1 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: REPL ($80.9M, 100.00%), PYXS ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | REPL | Replimune Group Inc. | $80.9M | 100.00% | 7.3M | New |
| 2 | PYXS | Pyxis Oncology Inc | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30